跳转至内容
Merck

F0120000

氟卡尼 乙酸盐

European Pharmacopoeia (EP) Reference Standard

别名:

N -(2-哌啶基甲基)-2,5--(2,2,2-三氟乙氧基)苯甲酰胺 乙酸盐

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C17H20F6N2O3 · C2H4O2
CAS号:
分子量:
474.39
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

flecainide

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

CC(O)=O.FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC2CCCCN2

InChI

1S/C17H20F6N2O3.C2H4O2/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11;1-2(3)4/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26);1H3,(H,3,4)

InChI 密鑰

RKXNZRPQSOPPRN-UHFFFAOYSA-N

基因資訊

human ... SCN5A(6331)

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Flecainide acetate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Health hazardExclamation mark

訊號詞

Danger

危險分類

Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2 - STOT SE 3

標靶器官

Respiratory system

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

P Maury et al.
Archives des maladies du coeur et des vaisseaux, 92(2), 273-277 (1999-03-17)
Poisoning with flecainide acetate is rare and associated with a high mortality. This usually occurs after massive ingestion but can also be observed during therapeutic overdose in patients with renal failure or with amiodarone therapy. The prognostic depends on the
S Senior et al.
Heart & lung : the journal of critical care, 17(1), 76-80 (1988-01-01)
Flecainide may play an important role in the treatment of ventricular arrhythmias because of its convenient dosing regimen and high rate of efficacy in controlling ventricular ectopic activity. In stable patients with normal or mildly reduced left ventricular function, flecainide
P Bordier et al.
Annales de cardiologie et d'angeiologie, 45(5), 263-279 (1996-05-01)
Flecainide acetate is a powerful antiarrhythmic initially used to treat ventricular arrhythmias. Despite an excess mortality in this indication and in the presence of heart disease, flecainide remains a good antiarrhythmic for supraventricular tachycardias in a healthy heart.
J C Perry et al.
American heart journal, 124(6), 1614-1621 (1992-12-11)
A review of all published experience with flecainide in infants, children, and fetuses was performed to evaluate the appropriate place of the drug in pediatric practice and to determine dosing guidelines. A total of 704 case references was generated. Flecainide
D Mehta et al.
Cardiovascular drugs and therapy, 1(6), 599-603 (1988-03-01)
Flecainide acetate depresses the rate of depolarization of action potential (Vmax), the so-called "membrane stabilizing action." In the intact heart it has a unique profile of substantial effect on conduction with modest effect on refractoriness. After intravenous administration, clinical electrophysiologic

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门